Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Stein Christian Mohn | M | - |
Cytovation AS
Cytovation AS Miscellaneous Commercial ServicesCommercial Services Cytovation AS is a Norwegian clinical stage immune-oncology company that focuses on developing Cypep-1, a first-in-class immunotherapy that targets the cell membrane of tumor cells. The company is a spin-off from the University of Bergen and is headquartered in Bergen, Norway. Cypep-1 has a unique mechanism of action that eliminates cancer cells by forming pores in the plasma membrane, releasing antigens to the immune system, promoting an inflammatory microenvironment, and inducing a tumor-specific immune response by in situ vaccination. Cytovation develops treatments for solid tumors in oncology and rare diseases, building on over 15 years of cutting-edge research. The CEO is Lars Prestegarden, and the company was founded by Rolf Bjerkvig, Per Eystein, and Stein Christian Mohn. | - |
Rolf Bjerkvig | M | - |
Cytovation AS
Cytovation AS Miscellaneous Commercial ServicesCommercial Services Cytovation AS is a Norwegian clinical stage immune-oncology company that focuses on developing Cypep-1, a first-in-class immunotherapy that targets the cell membrane of tumor cells. The company is a spin-off from the University of Bergen and is headquartered in Bergen, Norway. Cypep-1 has a unique mechanism of action that eliminates cancer cells by forming pores in the plasma membrane, releasing antigens to the immune system, promoting an inflammatory microenvironment, and inducing a tumor-specific immune response by in situ vaccination. Cytovation develops treatments for solid tumors in oncology and rare diseases, building on over 15 years of cutting-edge research. The CEO is Lars Prestegarden, and the company was founded by Rolf Bjerkvig, Per Eystein, and Stein Christian Mohn. | - |
Kristian Falnes | M | 61 |
SKAGEN AS
SKAGEN AS Investment ManagersFinance Part of Storebrand ASA, SKAGEN AS is a Norwegian fund management company. The company is based in Stavanger, Norway. SKAGEN was founded by Kristoffer Stensrud, Geir Tjetland, Åge Kristiansen Westbø, Tor Dagfinn Veen. Timothy Warrington has been the CEO of the company since 2007. | 7 years |
Kathinka Koch Sommerseth | F | - |
SKAGEN AS
SKAGEN AS Investment ManagersFinance Part of Storebrand ASA, SKAGEN AS is a Norwegian fund management company. The company is based in Stavanger, Norway. SKAGEN was founded by Kristoffer Stensrud, Geir Tjetland, Åge Kristiansen Westbø, Tor Dagfinn Veen. Timothy Warrington has been the CEO of the company since 2007. | - |
Lars Prestegarden | M | - |
Cytovation AS
Cytovation AS Miscellaneous Commercial ServicesCommercial Services Cytovation AS is a Norwegian clinical stage immune-oncology company that focuses on developing Cypep-1, a first-in-class immunotherapy that targets the cell membrane of tumor cells. The company is a spin-off from the University of Bergen and is headquartered in Bergen, Norway. Cypep-1 has a unique mechanism of action that eliminates cancer cells by forming pores in the plasma membrane, releasing antigens to the immune system, promoting an inflammatory microenvironment, and inducing a tumor-specific immune response by in situ vaccination. Cytovation develops treatments for solid tumors in oncology and rare diseases, building on over 15 years of cutting-edge research. The CEO is Lars Prestegarden, and the company was founded by Rolf Bjerkvig, Per Eystein, and Stein Christian Mohn. | - |
Kjell-Inge Arnevig | M | - |
Cytovation AS
Cytovation AS Miscellaneous Commercial ServicesCommercial Services Cytovation AS is a Norwegian clinical stage immune-oncology company that focuses on developing Cypep-1, a first-in-class immunotherapy that targets the cell membrane of tumor cells. The company is a spin-off from the University of Bergen and is headquartered in Bergen, Norway. Cypep-1 has a unique mechanism of action that eliminates cancer cells by forming pores in the plasma membrane, releasing antigens to the immune system, promoting an inflammatory microenvironment, and inducing a tumor-specific immune response by in situ vaccination. Cytovation develops treatments for solid tumors in oncology and rare diseases, building on over 15 years of cutting-edge research. The CEO is Lars Prestegarden, and the company was founded by Rolf Bjerkvig, Per Eystein, and Stein Christian Mohn. | - |
Aina Haug | F | - |
SKAGEN AS
SKAGEN AS Investment ManagersFinance Part of Storebrand ASA, SKAGEN AS is a Norwegian fund management company. The company is based in Stavanger, Norway. SKAGEN was founded by Kristoffer Stensrud, Geir Tjetland, Åge Kristiansen Westbø, Tor Dagfinn Veen. Timothy Warrington has been the CEO of the company since 2007. | - |
Per Gustav Blom | M | - |
SKAGEN AS
SKAGEN AS Investment ManagersFinance Part of Storebrand ASA, SKAGEN AS is a Norwegian fund management company. The company is based in Stavanger, Norway. SKAGEN was founded by Kristoffer Stensrud, Geir Tjetland, Åge Kristiansen Westbø, Tor Dagfinn Veen. Timothy Warrington has been the CEO of the company since 2007. | - |
Tim Warrington | M | - |
SKAGEN AS
SKAGEN AS Investment ManagersFinance Part of Storebrand ASA, SKAGEN AS is a Norwegian fund management company. The company is based in Stavanger, Norway. SKAGEN was founded by Kristoffer Stensrud, Geir Tjetland, Åge Kristiansen Westbø, Tor Dagfinn Veen. Timothy Warrington has been the CEO of the company since 2007. | 17 years |
Jan Erik Saugestad | M | 59 |
SKAGEN AS
SKAGEN AS Investment ManagersFinance Part of Storebrand ASA, SKAGEN AS is a Norwegian fund management company. The company is based in Stavanger, Norway. SKAGEN was founded by Kristoffer Stensrud, Geir Tjetland, Åge Kristiansen Westbø, Tor Dagfinn Veen. Timothy Warrington has been the CEO of the company since 2007. | - |
Raj Airey | M | - |
Cytovation AS
Cytovation AS Miscellaneous Commercial ServicesCommercial Services Cytovation AS is a Norwegian clinical stage immune-oncology company that focuses on developing Cypep-1, a first-in-class immunotherapy that targets the cell membrane of tumor cells. The company is a spin-off from the University of Bergen and is headquartered in Bergen, Norway. Cypep-1 has a unique mechanism of action that eliminates cancer cells by forming pores in the plasma membrane, releasing antigens to the immune system, promoting an inflammatory microenvironment, and inducing a tumor-specific immune response by in situ vaccination. Cytovation develops treatments for solid tumors in oncology and rare diseases, building on over 15 years of cutting-edge research. The CEO is Lars Prestegarden, and the company was founded by Rolf Bjerkvig, Per Eystein, and Stein Christian Mohn. | - |
Liv Hege Dyrnes | F | 44 |
Cytovation AS
Cytovation AS Miscellaneous Commercial ServicesCommercial Services Cytovation AS is a Norwegian clinical stage immune-oncology company that focuses on developing Cypep-1, a first-in-class immunotherapy that targets the cell membrane of tumor cells. The company is a spin-off from the University of Bergen and is headquartered in Bergen, Norway. Cypep-1 has a unique mechanism of action that eliminates cancer cells by forming pores in the plasma membrane, releasing antigens to the immune system, promoting an inflammatory microenvironment, and inducing a tumor-specific immune response by in situ vaccination. Cytovation develops treatments for solid tumors in oncology and rare diseases, building on over 15 years of cutting-edge research. The CEO is Lars Prestegarden, and the company was founded by Rolf Bjerkvig, Per Eystein, and Stein Christian Mohn. | 2 years |
Øyvind Kongstun Arnesen | M | 67 |
Cytovation AS
Cytovation AS Miscellaneous Commercial ServicesCommercial Services Cytovation AS is a Norwegian clinical stage immune-oncology company that focuses on developing Cypep-1, a first-in-class immunotherapy that targets the cell membrane of tumor cells. The company is a spin-off from the University of Bergen and is headquartered in Bergen, Norway. Cypep-1 has a unique mechanism of action that eliminates cancer cells by forming pores in the plasma membrane, releasing antigens to the immune system, promoting an inflammatory microenvironment, and inducing a tumor-specific immune response by in situ vaccination. Cytovation develops treatments for solid tumors in oncology and rare diseases, building on over 15 years of cutting-edge research. The CEO is Lars Prestegarden, and the company was founded by Rolf Bjerkvig, Per Eystein, and Stein Christian Mohn. | 2 years |
Viveka Marianne Ekberg | F | 62 |
SKAGEN AS
SKAGEN AS Investment ManagersFinance Part of Storebrand ASA, SKAGEN AS is a Norwegian fund management company. The company is based in Stavanger, Norway. SKAGEN was founded by Kristoffer Stensrud, Geir Tjetland, Åge Kristiansen Westbø, Tor Dagfinn Veen. Timothy Warrington has been the CEO of the company since 2007. | - |
Tove Selnes | F | 55 |
SKAGEN AS
SKAGEN AS Investment ManagersFinance Part of Storebrand ASA, SKAGEN AS is a Norwegian fund management company. The company is based in Stavanger, Norway. SKAGEN was founded by Kristoffer Stensrud, Geir Tjetland, Åge Kristiansen Westbø, Tor Dagfinn Veen. Timothy Warrington has been the CEO of the company since 2007. | - |
Leiv Askvig | M | 67 |
SKAGEN AS
SKAGEN AS Investment ManagersFinance Part of Storebrand ASA, SKAGEN AS is a Norwegian fund management company. The company is based in Stavanger, Norway. SKAGEN was founded by Kristoffer Stensrud, Geir Tjetland, Åge Kristiansen Westbø, Tor Dagfinn Veen. Timothy Warrington has been the CEO of the company since 2007. | - |
Egil Herman Sjursen | M | - |
Cytovation AS
Cytovation AS Miscellaneous Commercial ServicesCommercial Services Cytovation AS is a Norwegian clinical stage immune-oncology company that focuses on developing Cypep-1, a first-in-class immunotherapy that targets the cell membrane of tumor cells. The company is a spin-off from the University of Bergen and is headquartered in Bergen, Norway. Cypep-1 has a unique mechanism of action that eliminates cancer cells by forming pores in the plasma membrane, releasing antigens to the immune system, promoting an inflammatory microenvironment, and inducing a tumor-specific immune response by in situ vaccination. Cytovation develops treatments for solid tumors in oncology and rare diseases, building on over 15 years of cutting-edge research. The CEO is Lars Prestegarden, and the company was founded by Rolf Bjerkvig, Per Eystein, and Stein Christian Mohn. | - |
Kjell Bernstrøm | M | - |
Cytovation AS
Cytovation AS Miscellaneous Commercial ServicesCommercial Services Cytovation AS is a Norwegian clinical stage immune-oncology company that focuses on developing Cypep-1, a first-in-class immunotherapy that targets the cell membrane of tumor cells. The company is a spin-off from the University of Bergen and is headquartered in Bergen, Norway. Cypep-1 has a unique mechanism of action that eliminates cancer cells by forming pores in the plasma membrane, releasing antigens to the immune system, promoting an inflammatory microenvironment, and inducing a tumor-specific immune response by in situ vaccination. Cytovation develops treatments for solid tumors in oncology and rare diseases, building on over 15 years of cutting-edge research. The CEO is Lars Prestegarden, and the company was founded by Rolf Bjerkvig, Per Eystein, and Stein Christian Mohn. | 2 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Per Eystein | M | - |
Cytovation AS
Cytovation AS Miscellaneous Commercial ServicesCommercial Services Cytovation AS is a Norwegian clinical stage immune-oncology company that focuses on developing Cypep-1, a first-in-class immunotherapy that targets the cell membrane of tumor cells. The company is a spin-off from the University of Bergen and is headquartered in Bergen, Norway. Cypep-1 has a unique mechanism of action that eliminates cancer cells by forming pores in the plasma membrane, releasing antigens to the immune system, promoting an inflammatory microenvironment, and inducing a tumor-specific immune response by in situ vaccination. Cytovation develops treatments for solid tumors in oncology and rare diseases, building on over 15 years of cutting-edge research. The CEO is Lars Prestegarden, and the company was founded by Rolf Bjerkvig, Per Eystein, and Stein Christian Mohn. | - |
Statistics
Country | Connections | % of total |
---|---|---|
Norway | 19 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Hilde Hukkelberg
- Personal Network